Wayne Kuznar | Authors


Frontline Acalabrutinib Improves Quality-Adjusted Survival in CLL

November 03, 2021

Patients treated with acalabrutinib monotherapy had a significantly longer mean duration of time spent without toxicity compared with those treated with chlorambucil plus obinutuzumab in the phase 3 ELEVATE-TN trial.

Targeted Agents, Immunotherapies Are Advancing to the Adjuvant Setting in Solid Tumors

September 20, 2021

After success in malignant melanoma and non–small cell lung cancer, adjuvant treatments are demonstrating improvements in disease-free survival in other cancers, including renal cell carcinoma, esophageal/gastroesophageal cancer, and breast cancer.

Improved Responses Seen with Mobocertinib Vs Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLC

September 16, 2021

Compared indirectly with real-world data of patients treated with standard of care, mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy.